| Colorectal Carcinoma

Opdivo vs Keytruda

Side-by-side clinical, coverage, and cost comparison for colorectal carcinoma.

Deep comparison between: Opdivo vs Keytruda with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsKeytruda has a higher rate of injection site reactions vs Opdivo based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Keytruda but not Opdivo, including UnitedHealthcare

Category

Opdivo

Keytruda

At A Glance

RouteIV infusion

FrequencyEvery 2 weeks or Every 4 weeks

ClassPD-1 blocking antibody

RouteIV infusion

FrequencyEvery 3 weeks or Every 6 weeks

ClassPD-1 inhibitor

Indications

melanoma
Non-Small Cell Lung Carcinoma
Malignant Pleural Mesothelioma
Renal Cell Carcinoma
Hodgkin Disease
Squamous cell carcinoma of the head and neck
Urothelial Carcinoma
Colorectal Carcinoma
Liver carcinoma
Squamous cell carcinoma of esophagus
Stomach Carcinoma
Gastroesophageal junction cancer
Adenocarcinoma Of Esophagus

melanoma
Non-Small Cell Lung Carcinoma
Malignant Pleural Mesothelioma
Squamous cell carcinoma of the head and neck
Classic Hodgkin Lymphoma
Mediastinal (Thymic) Large B-Cell Lymphoma
Urothelial Carcinoma
Colorectal Carcinoma
Stomach Carcinoma
Esophageal carcinoma
Cervix carcinoma
Liver carcinoma
Biliary Tract Cancer
Merkel cell carcinoma
Renal Cell Carcinoma
Endometrial Carcinoma
Triple-Negative Breast Carcinoma
Malignant neoplasm of ovary
Squamous cell carcinoma of skin

Dosing

Melanoma Adults and pediatric >=40 kg: 240 mg every 2 weeks or 480 mg every 4 weeks; Pediatric <40 kg: 3 mg/kg every 2 weeks or 6 mg/kg every 4 weeks

Non-Small Cell Lung Carcinoma Neoadjuvant: 360 mg every 3 weeks with platinum-doublet chemotherapy for 3-4 cycles; Adjuvant after neoadjuvant: 480 mg every 4 weeks; Metastatic: 360 mg every 3 weeks with ipilimumab 1 mg/kg every 6 weeks; or 360 mg every 3 weeks with ipilimumab 1 mg/kg every 6 weeks and 2 cycles platinum-doublet chemotherapy; or 240 mg every 2 weeks or 480 mg every 4 weeks

Malignant Pleural Mesothelioma 360 mg every 3 weeks with ipilimumab 1 mg/kg every 6 weeks

Renal Cell Carcinoma 3 mg/kg with ipilimumab 1 mg/kg every 3 weeks for 4 doses, then 240 mg every 2 weeks or 480 mg every 4 weeks; or 240 mg every 2 weeks or 480 mg every 4 weeks with cabozantinib 40 mg daily orally; or 240 mg every 2 weeks or 480 mg every 4 weeks

Hodgkin Disease Previously untreated: Adults and pediatric >=40 kg: 240 mg with AVD every 2 weeks for 6 cycles; Pediatric <40 kg: 3 mg/kg with AVD every 2 weeks for 6 cycles; Relapsed or refractory: 240 mg every 2 weeks or 480 mg every 4 weeks

Squamous cell carcinoma of the head and neck 240 mg every 2 weeks or 480 mg every 4 weeks

Urothelial Carcinoma Adjuvant: 240 mg every 2 weeks or 480 mg every 4 weeks; First-line: 360 mg every 3 weeks with cisplatin and gemcitabine for up to 6 cycles, then 240 mg every 2 weeks or 480 mg every 4 weeks; Previously treated: 240 mg every 2 weeks or 480 mg every 4 weeks

Colorectal Carcinoma Adults and pediatric >=40 kg: 240 mg with ipilimumab 1 mg/kg every 3 weeks for maximum 4 doses, then 240 mg every 2 weeks or 480 mg every 4 weeks; Pediatric <40 kg: 3 mg/kg with ipilimumab 1 mg/kg every 3 weeks for maximum 4 doses, then 3 mg/kg every 2 weeks or 6 mg/kg every 4 weeks

Liver carcinoma 1 mg/kg with ipilimumab 3 mg/kg every 3 weeks for 4 doses, then 240 mg every 2 weeks or 480 mg every 4 weeks

Squamous cell carcinoma of esophagus Adjuvant resected: 240 mg every 2 weeks or 480 mg every 4 weeks for 1 year; First-line with chemotherapy: 240 mg every 2 weeks or 480 mg every 4 weeks with fluoropyrimidine- and platinum-containing chemotherapy; First-line with ipilimumab: 3 mg/kg every 2 weeks or 360 mg every 3 weeks with ipilimumab 1 mg/kg every 6 weeks; Previously treated: 240 mg every 2 weeks or 480 mg every 4 weeks

Stomach Carcinoma 360 mg every 3 weeks with fluoropyrimidine- and platinum-containing chemotherapy every 3 weeks or 240 mg every 2 weeks with fluoropyrimidine- and platinum-containing chemotherapy every 2 weeks

Gastroesophageal junction cancer 360 mg every 3 weeks with fluoropyrimidine- and platinum-containing chemotherapy every 3 weeks or 240 mg every 2 weeks with fluoropyrimidine- and platinum-containing chemotherapy every 2 weeks

Adenocarcinoma Of Esophagus 360 mg every 3 weeks with fluoropyrimidine- and platinum-containing chemotherapy every 3 weeks or 240 mg every 2 weeks with fluoropyrimidine- and platinum-containing chemotherapy every 2 weeks

melanoma 200 mg every 3 weeks or 400 mg every 6 weeks IV; 2 mg/kg (up to 200 mg) every 3 weeks IV for pediatrics

Non-Small Cell Lung Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV

Malignant Pleural Mesothelioma 200 mg every 3 weeks or 400 mg every 6 weeks IV

Squamous cell carcinoma of the head and neck 200 mg every 3 weeks or 400 mg every 6 weeks IV

Classic Hodgkin Lymphoma 200 mg every 3 weeks or 400 mg every 6 weeks IV for adults; 2 mg/kg (up to 200 mg) every 3 weeks IV for pediatrics

Mediastinal (Thymic) Large B-Cell Lymphoma 200 mg every 3 weeks or 400 mg every 6 weeks IV for adults; 2 mg/kg (up to 200 mg) every 3 weeks IV for pediatrics

Urothelial Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV

Colorectal Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV for adults; 2 mg/kg (up to 200 mg) every 3 weeks IV for pediatrics

Stomach Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV

Esophageal carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV

Cervix carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV

Liver carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV

Biliary Tract Cancer 200 mg every 3 weeks or 400 mg every 6 weeks IV

Merkel cell carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV for adults; 2 mg/kg (up to 200 mg) every 3 weeks IV for pediatrics

Renal Cell Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV as single agent or in combination with axitinib 5 mg orally twice daily or lenvatinib 20 mg orally once daily

Endometrial Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV in combination with carboplatin and paclitaxel, or with lenvatinib 20 mg orally once daily, or as single agent for MSI-H or dMMR tumors

Triple-Negative Breast Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV

Malignant neoplasm of ovary 200 mg every 3 weeks or 400 mg every 6 weeks IV

Squamous cell carcinoma of skin 200 mg every 3 weeks or 400 mg every 6 weeks IV

Contraindications

Drug Interactions

188View drug interactions

189View drug interactions

Adverse Reactions

Most common (>=20%) fatigue, musculoskeletal pain, rash, diarrhea, pruritus, nausea, decreased appetite, cough, dyspnea, constipation, upper respiratory tract infection

Serious pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatologic reactions, myocarditis, neurological toxicities, infusion-related reactions

Most common (>=20%) fatigue, musculoskeletal pain, decreased appetite, rash, diarrhea, nausea, cough, dyspnea, constipation, pruritus, hypothyroidism

Serious pneumonitis, colitis, hepatitis, endocrinopathies, nephritis with renal dysfunction, dermatologic adverse reactions, myocarditis, neurological toxicities, infusion-related reactions, immune-mediated adverse reactions

Postmarketing exocrine pancreatic insufficiency, sclerosing cholangitis

Pharmacology

Nivolumab is a PD-1 blocking antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.

Pembrolizumab is a PD-1 blocking antibody that releases PD-1 pathway-mediated inhibition of the immune response by preventing the interaction of PD-1 with its ligands PD-L1 and PD-L2, thereby restoring anti-tumor immune response.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Opdivo